New NICE Prostate Cancer Guideline Focuses on Quality of Life Issues
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




New NICE Prostate Cancer Guideline Focuses on Quality of Life Issues

LONDON -- February 27, 2008 -- The National Institute for Health and Clinical Excellence (NICE) has a new guideline on best practice for the diagnosis and treatment of prostate cancer.

The guideline, produced for NICE by the National Collaborating Centre for Cancer, will help clinicians to provide coherent and consistent care for men with suspected or diagnosed prostate cancer across England and Wales.

Recommendations include:
· Men with prostate cancer, as well as their partners or carers, should be informed how prostate cancer and their treatment options will affect their sexual function, physical appearance, continence, and other aspects of masculinity. Men should be supported to make treatment decisions that take into account both the effects on quality of life as well as survival.

· To help men decide whether to have a prostate biopsy, healthcare professionals should discuss with them their prostate specific antigen (PSA) level, digital rectal examination (DRE) results, and comorbidities, together with their risk factors (including increasing age and black African or black Caribbean ethnicity) and any history of a previous negative prostate biopsy. The serum PSA level alone should not automatically lead to a prostate biopsy.

· Men with low-risk localised prostate cancer who are considered suitable for radical treatment should first be offered active surveillance.

· Healthcare professionals should ensure that men and their partners have early and ongoing access to specialist erectile dysfunction services.

· Healthcare professionals should ensure that men with troublesome urinary symptoms after treatment have access to specialist continence services for assessment, diagnosis, and conservative treatment.

· When men with prostate cancer develop biochemical evidence of hormone-refractory disease, their treatment options should be discussed by the urological cancer multidisciplinary team with a view to seeking an oncologist and/or specialist palliative care opinion, as appropriate.

SOURCE: National Institute for Health and Clinical Excellence

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities